<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CTJ</journal-id>
<journal-id journal-id-type="hwp">spctj</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Trials</journal-id>
<journal-title>Clinical Trials</journal-title>
<issn pub-type="ppub">1740-7745</issn>
<issn pub-type="epub">1740-7753</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1740774513485311</article-id>
<article-id pub-id-type="publisher-id">10.1177_1740774513485311</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Summarizing the incidence of adverse events using volcano plots and time intervals</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zink</surname><given-names>Richard C</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Wolfinger</surname><given-names>Russell D</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Mann</surname><given-names>Geoffrey</given-names></name>
</contrib>
<aff id="aff1-1740774513485311">JMP Life Sciences, SAS Institute, Inc., Cary, NC, USA</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1740774513485311">Richard C Zink, JMP Life Sciences, SAS Institute, Inc., SAS Campus Drive, Cary, NC 27513, USA. Email: <email>richard.zink@jmp.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>10</volume>
<issue>3</issue>
<fpage>398</fpage>
<lpage>406</lpage>
<permissions>
<copyright-statement>© The Author(s), 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">The Society for Clinical Trials</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1740774513485311">
<title>Background</title>
<p>Adverse event incidence analyses are a critical component for describing the safety profile of any new intervention. The results typically are presented in lengthy summary tables. For therapeutic areas where patients have frequent adverse events, analysis and interpretation are made more difficult by the sheer number and variety of events that occur. Understanding the risk in these instances becomes even more crucial.</p>
</sec>
<sec id="section2-1740774513485311">
<title>Purpose</title>
<p>We describe a space-saving graphical summary that overcomes the limitations of traditional presentations of adverse events and improves interpretability of the safety profile.</p>
</sec>
<sec id="section3-1740774513485311">
<title>Methods</title>
<p>We present incidence analyses of adverse events graphically using volcano plots to highlight treatment differences. Data from a clinical trial of patients experiencing an aneurysmal subarachnoid hemorrhage are used for illustration. Adjustments for multiplicity are illustrated.</p>
</sec>
<sec id="section4-1740774513485311">
<title>Results</title>
<p>Color is used to indicate the treatment with higher incidence; bubble size represents the total number of events that occur in the treatment arms combined. Adjustments for multiple comparisons are displayed in a manner to indicate clearly those events for which the difference between treatment arms is statistically significant. Furthermore, adverse events can be displayed by time intervals, with multiple volcano plots or animation to appreciate changes in adverse event risk over time. Such presentations can emphasize early differences across treatments that may resolve later or highlight events for which treatment differences may become more substantial with longer follow-up.</p>
</sec>
<sec id="section5-1740774513485311">
<title>Limitations</title>
<p>Treatment arms are compared in a pairwise fashion.</p>
</sec>
<sec id="section6-1740774513485311">
<title>Conclusions</title>
<p>Volcano plots are space-saving tools that emphasize important differences between the adverse event profiles of two treatment arms. They can incorporate multiplicity adjustments in a manner that is straightforward to interpret and, by using time intervals, can illustrate how adverse event risk changes over the course of a clinical trial.</p>
</sec>
</abstract>
</article-meta>
</front>
<body>
<sec id="section7-1740774513485311" sec-type="intro">
<title>Introduction</title>
<p>There are numerous considerations in the analysis of adverse events in a clinical trial. While it may be possible to prespecify a subset of events likely to occur on study for a given therapeutic area, there are many other events that may arise and that require analysis and interpretation in order to understand the safety profile of a new intervention. Disease severity, trial duration, and the number of patients under investigation contribute to the sheer number and variety of events that occur, all of which complicate the safety assessment. Furthermore, while many procedures may be performed at regular intervals throughout the trial, such as a physical examination at every study visit, adverse events occur haphazardly across time. Coupled with the rarity of many events, their unpredictable timing and nature make it difficult to gain insight into how risk changes over time.</p>
<p>Traditionally, the incidence of adverse events is presented in lengthy summary tables, with coded event terms grouped by body system or system organ class and presented in order of descending frequency within group. An abbreviated example is provided in <xref ref-type="table" rid="table1-1740774513485311">Table 1</xref> using data from Ref. [<xref ref-type="bibr" rid="bibr1-1740774513485311">1</xref>]. Further tables may highlight events that occur during specific periods of time (e.g., treatment phase or off-treatment follow-up), or summarize how event severity or relationship to study medication affects study results. It is difficult to summarize this information to gain a clear understanding of the risk (or benefit) a new therapy may present.</p>
<table-wrap id="table1-1740774513485311" position="float">
<label>Table 1.</label>
<caption>
<p>Incidence of treatment-emergent adverse events</p>
</caption>
<graphic alternate-form-of="table1-1740774513485311" xlink:href="10.1177_1740774513485311-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Nicardipine (<italic>n</italic> = 447)</th>
<th align="left">Placebo (<italic>n</italic> = 455)</th>
</tr>
</thead>
<tbody>
<tr>
<td>
<italic>Blood and lymphatic system disorders</italic>
</td>
<td>195 (44)</td>
<td>203 (45)</td>
</tr>
<tr>
<td> Anaemia</td>
<td>137 (31)</td>
<td>160 (35)</td>
</tr>
<tr>
<td> Platelet destruction increased</td>
<td>29 (6)</td>
<td>16 (4)</td>
</tr>
<tr>
<td> (5 more)</td>
<td/>
<td/>
</tr>
<tr>
<td>
<italic>Cardiac disorders</italic>
</td>
<td>156 (35)</td>
<td>175 (38)</td>
</tr>
<tr>
<td> Ventricular extrasystoles</td>
<td>39 (9)</td>
<td>41 (9)</td>
</tr>
<tr>
<td> Sinus bradycardia</td>
<td>15 (3)</td>
<td>41 (9)</td>
</tr>
<tr>
<td> (24 more)</td>
<td/>
<td/>
</tr>
<tr>
<td>
<italic>Gastrointestinal disorders</italic>
</td>
<td>95 (21)</td>
<td>90 (20)</td>
</tr>
<tr>
<td> Vomiting</td>
<td>59 (13)</td>
<td>61 (13)</td>
</tr>
<tr>
<td> Gastrointestinal haemorrhage</td>
<td>17 (4)</td>
<td>10 (2)</td>
</tr>
<tr>
<td> (14 more)</td>
<td/>
<td/>
</tr>
<tr>
<td>
<italic>19 more system organ classes</italic>
</td>
<td/>
<td/>
</tr>
<tr>
<td> 147 more preferred terms</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1740774513485311">
<p>Values are frequency (percentage).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The analysis of adverse events, like many areas of safety in clinical trials, can benefit from the use of graphical displays to convey large amounts of information. For adverse events, Amit and co-authors suggest a display that combines a dot plot to present the incidence of each event, coupled with a relative risk plot to illustrate differences between two treatments [<xref ref-type="bibr" rid="bibr2-1740774513485311">2</xref>,<xref ref-type="bibr" rid="bibr3-1740774513485311">3</xref>]. For example, <xref ref-type="fig" rid="fig1-1740774513485311">Figure 1</xref> displays events in order of decreasing risk for the test treatment. In <xref ref-type="fig" rid="fig1-1740774513485311">Figure 1</xref>, the relative risk is presented on the log<sub>2</sub> scale so that every unit difference represents a doubling of the risk ratio between the treatments. Confidence intervals that contain zero would be interpreted as showing no difference in risk between the two treatments, while those contained completely within the red or blue region would show increased risk for drug or placebo, respectively. While this plot is useful, its <italic>y</italic>-axis can become quite lengthy when there are numerous adverse events. Such a display is impractical when events are to be presented by time intervals.</p>
<fig id="fig1-1740774513485311" position="float">
<label>Figure 1.</label>
<caption>
<p>Adverse event dot plot and relative risk plot. The left side of the figure displays the percentage of patients exhibiting a treatment-emergent adverse event for nicardipine (triangle) or placebo (circle). In the right side of the figure, confidence intervals for the log<sub>2</sub>(relative risk) that contain zero would be interpreted as showing no difference in risk between the two treatments, while those contained completely within the red or blue region would show increased risk for drug or placebo, respectively. Every unit increase of the log<sub>2</sub>(relative risk) represents a doubling of the risk ratio between the treatments.</p>
</caption>
<graphic xlink:href="10.1177_1740774513485311-fig1.tif"/>
</fig>
<p>As an alternative display, we propose the use of volcano plots for the analysis of adverse events [<xref ref-type="bibr" rid="bibr4-1740774513485311">4</xref>]. Volcano plots have numerous benefits in that they are space-saving, can easily incorporate and display multiplicity adjustments, and can accentuate changes in risk over time. Perhaps most important, volcano plots emphasize important safety findings while minimizing noise, thus aiding in the interpretation of large amounts of information for the clinical study report. We illustrate the use of volcano plots with an analysis of data from a clinical trial of delayed cerebral vasospasm in patients who experienced an aneurysmal subarachnoid hemorrhage (bleeding between the brain and tissues that cover the brain) [<xref ref-type="bibr" rid="bibr1-1740774513485311">1</xref>].</p>
<p>When numerous tests are performed, multiplicity or multiple comparisons is a key concern in the field of statistics. Most of us are comfortable with the idea that a <italic>p</italic>-value ≤ 0.05 denotes a statistically significant test, one in which we reject the null hypothesis in favor of the alternative with 95% confidence. Here, we accept the possibility that there is a 1 in 20 chance that we incorrectly reject the null hypothesis (a so-called type I error). However, when multiple tests are performed within the same experiment, each at the 0.05 level, the above explanation falls apart. For example, if 20 tests are performed, we can expect one significant result where the null hypothesis was incorrectly rejected, so claims that we have a 1 in 20 chance of an incorrect conclusion are rather meaningless. In order to maintain our 95% confidence for a set of tests, adjustments to the alpha levels (shrinking) for each test are required.</p>
<p>Multiplicity is an important consideration in the analysis of adverse events, as for safety analyses in general. Not only are there a large number of endpoints, but many safety endpoints are measured repeatedly over the course of a clinical trial, further complicating the multiplicity problem. In addition, many potential safety endpoints, such as adverse events, occur spontaneously throughout the trial making the prespecification of many hypotheses impossible. Experience with the therapeutic area or drug class under investigation or knowledge of competitor products may suggest adverse events likely to occur. However, unanticipated events may occur. Below, we describe how volcano plots can incorporate multiplicity adjustments in a manner that is straightforward to interpret.</p>
</sec>
<sec id="section8-1740774513485311" sec-type="methods">
<title>Methods</title>
<sec id="section9-1740774513485311">
<title>Data</title>
<p>The 902 treated patients of the nicardipine clinical trial experienced a total of 5963 treatment-emergent adverse events (events that occurred on or after the first day of dosing) [<xref ref-type="bibr" rid="bibr1-1740774513485311">1</xref>]. Coding with the Medical Dictionary for Regulatory Activities (MedDRA) led to 196 distinct preferred terms contained within 22 system organ classes. This classification of adverse event terms into preferred terms and system organ classes will be used throughout the analyses and figures in this article. While the analysis of adverse events hinges on the quality of this coding step, the mechanics and issues surrounding this activity are outside the scope of the article.</p>
</sec>
<sec id="section10-1740774513485311">
<title>Volcano plots</title>
<p>The term ‘volcano plot’ was first used in Ref. [<xref ref-type="bibr" rid="bibr4-1740774513485311">4</xref>] to quantify the impact of approximately 4000 genes on various covariates in a microarray expression experiment for <italic>Drosophila melanogaster</italic>. In the context of a clinical trial, safety analyses often have a large number of endpoints to summarize and interpret. For example, a volcano plot summarizing the incidence of adverse events using data from Ref. [<xref ref-type="bibr" rid="bibr1-1740774513485311">1</xref>] is presented in <xref ref-type="fig" rid="fig2-1740774513485311">Figure 2</xref>. <xref ref-type="fig" rid="fig2-1740774513485311">Figure 2</xref> differs in two important ways from the volcano plots suggested in Ref. [<xref ref-type="bibr" rid="bibr4-1740774513485311">4</xref>]. First, each bubble represents an adverse event, with bubble size indicative of the total number of adverse events that occur for both treatments combined. Specifically, the radius of any bubble is proportional to the square-root of the event frequency, so that the bubble area is proportional to the total number of events. As shown in <xref ref-type="fig" rid="fig2-1740774513485311">Figure 2</xref>, vasoconstriction was the most commonly occurring adverse event during this trial. Second, color (here, red and blue) helps to emphasize adverse events that are more common for nicardipine and placebo, respectively. Furthermore, the color saturation corresponds to the statistical significance of the risk difference for each adverse event. Volcano plots are straightforward to produce in SAS, JMP and R using various procedures for bubble plots. Alternatively, if there is no need to size the bubbles based on event frequency, any procedure for generating scatter plots should suffice since the volcano shape is obtained using −log<sub>10</sub>(<italic>p</italic>-value) along the <italic>y</italic>-axis. Figures were generated using JMP Clinical 4.0.</p>
<fig id="fig2-1740774513485311" position="float">
<label>Figure 2.</label>
<caption>
<p>Volcano plot of treatment-emergent adverse events. The <italic>x</italic>-axis represents the difference in proportions for each adverse event and the <italic>y</italic>-axis represents the −log<sub>10</sub>(raw <italic>p</italic>-value). The center of the circle denotes the coordinates for a particular adverse event, and the bubble area is proportional to the total number of events for both treatment arms combined. Red or blue implies greater risk for nicardipine or placebo, respectively. The dashed red line, drawn at 2.86, is equivalent to a <italic>p</italic>-value of 10<sup>−2.86</sup> = 0.0014. Events above this line are considered statistically significant when applying the FDR multiplicity adjustment.</p>
<p>FDR: false discovery rate.</p>
</caption>
<graphic xlink:href="10.1177_1740774513485311-fig2.tif"/>
</fig>
</sec>
<sec id="section11-1740774513485311">
<title>Multiplicity adjustments</title>
<p>Given the large number of potential comparisons of treatment arms for adverse events, Crowe and co-authors [<xref ref-type="bibr" rid="bibr5-1740774513485311">5</xref>] suggested a three-tier approach for the analysis of adverse events. Among their described strategies, they recommend that the detection of important differences among commonly occurring (in four or more patients in a single treatment arm) adverse events should consider multiple comparisons. Furthermore, Crowe and co-authors [<xref ref-type="bibr" rid="bibr5-1740774513485311">5</xref>] stated that the selected adjustment method should find a reasonable balance between committing type I errors without overly sacrificing the power to detect potential safety signals. Numerous methods of adjustment for multiplicity have been proposed to reduce the risk of type I errors. However, while many of these methods may control the familywise error rate, they are overly conservative due to the substantial loss of power that occurs when analyzing a large number of endpoints common to clinical trial safety analyses or in other settings, for example, genomics. This conservatism led to the development of the false discovery rate (FDR) method of Benjamini and Hochberg [<xref ref-type="bibr" rid="bibr6-1740774513485311">6</xref>], which provides a more balanced approach between type I error and power. Among the rejected null hypotheses from a family of multiple tests, the proportion of erroneous rejections is defined as the FDR. The FDR method controls this rate at a prespecified α, typically 0.05. However, unlike more common adjustment methods such as Bonferroni, the FDR adjustment typically does not control the overall familywise error rate, which leads to an increase in power among the individual comparisons. In general, with <italic>k</italic> treatment comparisons of ordered (smallest to largest) <italic>p</italic>-values <inline-formula id="inline-formula1-1740774513485311">
<mml:math display="block" id="math1-1740774513485311">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula>, the FDR <italic>p</italic>-value for the <italic>i</italic>th hypothesis is</p>
<p>
<disp-formula id="disp-formula1-1740774513485311">
<mml:math display="block" id="math2-1740774513485311">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>=</mml:mo>
<mml:mrow>
<mml:mo>{</mml:mo>
<mml:mtable align="left">
<mml:mtr>
<mml:mtd columnalign="center">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>k</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:mtd>
<mml:mtd>
<mml:mrow>
<mml:mtext>for</mml:mtext>
<mml:mspace width="0.25em"/>
<mml:mi>i</mml:mi>
<mml:mo>=</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd columnalign="center" columnspan="1">
<mml:mrow>
<mml:mo>min</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>,</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:mfrac>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:mtd>
<mml:mtd>
<mml:mrow>
<mml:mtext>for</mml:mtext>
<mml:mspace width="0.25em"/>
<mml:mi>i</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo>,</mml:mo>
<mml:mo>…</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>k</mml:mi>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:mrow>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-1740774513485311" xlink:href="10.1177_1740774513485311-eq1.tif"/>
</disp-formula>
</p>
<p>Crowe et al. recommended the double FDR (DFDR) multiplicity adjustment for the analysis of commonly occurring adverse events [<xref ref-type="bibr" rid="bibr5-1740774513485311">5</xref>,<xref ref-type="bibr" rid="bibr7-1740774513485311">7</xref>,<xref ref-type="bibr" rid="bibr8-1740774513485311">8</xref>]. The DFDR method applies the FDR concept while incorporating a grouping variable for the adverse events, such as MedDRA system organ class, into the analysis. Put simply, the method considers whether related terms (i.e., those in the same event group) exhibit differences between the treatments and upweights or downweights the importance of an individual term accordingly. In this way, comparisons between related events borrow strength from one another. In the original DFDR article, the FDR method was applied twice with a nonparametric bootstrap used to maintain FDR control [<xref ref-type="bibr" rid="bibr7-1740774513485311">7</xref>]. However, in a more recent article, the authors applied the FDR method three times without the previously needed simulations; as such, the method is more convenient to apply in practice [<xref ref-type="bibr" rid="bibr8-1740774513485311">8</xref>].</p>
<p>Suppose there are <italic>s</italic> classes of events with <inline-formula id="inline-formula2-1740774513485311">
<mml:math display="block" id="math3-1740774513485311">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> events in each class, <inline-formula id="inline-formula3-1740774513485311">
<mml:math display="block" id="math4-1740774513485311">
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>≤</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>≤</mml:mo>
<mml:mi>s</mml:mi>
</mml:mrow>
</mml:math></inline-formula>. To apply DFDR using the updated methodology, apply the following steps:</p>
<list id="list1-1740774513485311" list-type="order">
<list-item>
<p>Calculate <inline-formula id="inline-formula4-1740774513485311">
<mml:math display="block" id="math5-1740774513485311">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>ij</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math></inline-formula> as the FDR-adjusted <italic>p</italic>-values within each of <italic>s</italic> event groups;</p>
</list-item>
<list-item>
<p>Define <inline-formula id="inline-formula5-1740774513485311">
<mml:math display="block" id="math6-1740774513485311">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>=</mml:mo>
<mml:mtext>min</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>ij</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>,</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mn>1</mml:mn>
<mml:mo>≤</mml:mo>
<mml:mi>j</mml:mi>
<mml:mo>≤</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula>;</p>
</list-item>
<list-item>
<p>Calculate <inline-formula id="inline-formula6-1740774513485311">
<mml:math display="block" id="math7-1740774513485311">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math></inline-formula> as the FDR-adjusted <italic>p</italic>-values of <inline-formula id="inline-formula7-1740774513485311">
<mml:math display="block" id="math8-1740774513485311">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math></inline-formula>;</p>
</list-item>
<list-item>
<p>Define <inline-formula id="inline-formula8-1740774513485311">
<mml:math display="block" id="math9-1740774513485311">
<mml:mrow>
<mml:mi>F</mml:mi>
<mml:mo>=</mml:mo>
<mml:mrow>
<mml:mo>{</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>ij</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">|</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>≤</mml:mo>
<mml:mi>α</mml:mi>
<mml:mo>}</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math></inline-formula>. Calculate FDR-adjusted <italic>p</italic>-values <inline-formula id="inline-formula9-1740774513485311">
<mml:math display="block" id="math10-1740774513485311">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>ij</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>F</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math></inline-formula> for all <inline-formula id="inline-formula10-1740774513485311">
<mml:math display="block" id="math11-1740774513485311">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>ij</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> in <inline-formula id="inline-formula11-1740774513485311">
<mml:math display="block" id="math12-1740774513485311">
<mml:mrow>
<mml:mi>F</mml:mi>
</mml:mrow>
</mml:math></inline-formula>;</p>
</list-item>
<list-item>
<p>Events are significant if <inline-formula id="inline-formula12-1740774513485311">
<mml:math display="block" id="math13-1740774513485311">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>≤</mml:mo>
<mml:mi>α</mml:mi>
</mml:mrow>
</mml:math></inline-formula> and <inline-formula id="inline-formula13-1740774513485311">
<mml:math display="block" id="math14-1740774513485311">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>ij</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>F</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msubsup>
<mml:mo>≤</mml:mo>
<mml:mi>α</mml:mi>
</mml:mrow>
</mml:math></inline-formula>.</p>
</list-item>
</list>
</sec>
</sec>
<sec id="section12-1740774513485311" sec-type="results">
<title>Results</title>
<sec id="section13-1740774513485311">
<title>Volcano plots</title>
<p>The <italic>x</italic>-axis represents the difference in proportions for each adverse event, although this axis could represent other measures such as the log<sub>2</sub> relative risk or log<sub>2</sub> odds ratio. Alternatively, in lieu of collapsing the frequency of an event into a present/absent binary response for each patient, the <italic>x</italic>- and <italic>y</italic>-axes can be based on other statistics such as the log<sub>2</sub> incidence ratio, where the incidence for each treatment is the ratio of the total number of events experienced divided by some measure of exposure, such as patient-months on study [<xref ref-type="bibr" rid="bibr2-1740774513485311">2</xref>]. Another option would be to use the time to the first event along with −log<sub>10</sub><italic>p</italic>-values computed using survival methods. It is important to note that the center of the circle denotes the coordinates for a particular adverse event. The <italic>y</italic>-axis represents the −log<sub>10</sub>(raw <italic>p</italic>-value). To interpret the <italic>y</italic>-axis of <xref ref-type="fig" rid="fig2-1740774513485311">Figure 2</xref>, note that a <italic>p</italic>-value of 1 equals 0 on the −log<sub>10</sub> scale, a <italic>p</italic>-value of 0.1 equals 1 on the −log<sub>10</sub> scale, a <italic>p</italic>-value of 0.01 equals 2 on the −log<sub>10</sub> scale, a <italic>p</italic>-value of 0.001 equals 3 on the −log<sub>10</sub> scale, and a <italic>p</italic>-value of 0.0001 equals 4 on the −log<sub>10</sub> scale. The smaller the <italic>p</italic>-value, the larger the number on the <italic>y</italic>-axis; <italic>y</italic> can be thought of as the number of decimal places or number of zeros in the <italic>p</italic>-value derived from the comparison of risk by treatment arm. The log<sub>10</sub> transformation spreads out extreme differences between treatment arms along the <italic>y</italic>-axis. Otherwise, all very large risk differences, likely to be statistically significant, would be crowded near zero, making the events of interest difficult to view and interpret.</p>
<p>Multiplicity adjustments, such as the FDR and DFDR, are straightforward to display in volcano plots. In <xref ref-type="fig" rid="fig2-1740774513485311">Figure 2</xref>, adverse events with treatment differences that are considered statistically significant while adjusting for multiple comparisons using the FDR method are above the dashed red line, drawn at 2.86, equivalent to a <italic>p</italic>-value of 10<sup>−2.86</sup> = 0.0014. The volcano plot in the upper panel of <xref ref-type="fig" rid="fig3-1740774513485311">Figure 3</xref>, constructed after grouping adverse events by system organ class, shows the most statistically significant term for each system organ class, that is, vascular disorders and renal and urinary disorders. The volcano plot in the lower panel of <xref ref-type="fig" rid="fig3-1740774513485311">Figure 3</xref> presents all events from the two-system organ classes containing at least one statistically significant event. The differences for sinus bradycardia (cardiac disorders), pleural effusion (respiratory, thoracic, and mediastinal disorders), and agitation (psychiatric disorders) are no longer statistically significant in <xref ref-type="fig" rid="fig3-1740774513485311">Figure 3</xref> compared to <xref ref-type="fig" rid="fig2-1740774513485311">Figure 2</xref>. These particular system organ classes had 12, 8, and 3 other nonsignificant terms, respectively. In the right-hand panel of <xref ref-type="fig" rid="fig4-1740774513485311">Figure 4</xref>, the statistical significance line was drawn at 4.76, equivalent to a <italic>p</italic>-value of 10<sup>−4.76</sup> = 0.000017. Because unadjusted (raw) <italic>p</italic>-values from treatment arm comparisons are displayed, any particular adjustment line can be ignored if desired. Alternatively, multiple reference lines can be presented to highlight various adjustment strategies.</p>
<fig id="fig3-1740774513485311" position="float">
<label>Figure 3.</label>
<caption><p>Volcano plots of treatment-emergent adverse events using DFDR. The upper panel summarizes the significance of system organ classes for DFDR. The dashed red line, drawn at 3.98, is equivalent to a <italic>p</italic>-value of 10<sup>−3.98</sup> = 0.000105 (representing <inline-formula id="inline-formula14-1740774513485311">
<mml:math display="block" id="math15-1740774513485311">
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math></inline-formula>). The lower panel summarizes events from vascular disorders and renal and urinary disorders (considered significant from the upper panel). Here, the reference line is equivalent to a <italic>p</italic>-value of 10<sup>−4.76</sup> = 0.000017. DFDR: double false discovery rate.</p></caption>
<graphic xlink:href="10.1177_1740774513485311-fig3.tif"/></fig>
<fig id="fig4-1740774513485311" position="float">
<label>Figure 4.</label>
<caption>
<p>Volcano plots incorporating time intervals. Starting at upper-left-hand corner, volcano plots summarize the incidence of events in intervals for study days 1–3, 4–6, 7–9, and 10–12. Only events that are statistically significant (above the dashed red line) in at least one interval are displayed. The dashed red line, drawn at 2.86, is equivalent to a <italic>p</italic>-value of 10<sup>−2.86</sup> = 0.0014.</p>
</caption>
<graphic xlink:href="10.1177_1740774513485311-fig4.tif"/>
</fig>
</sec>
<sec id="section14-1740774513485311">
<title>Incorporating time intervals</title>
<p>The influence of time, which is related to the exposure to study intervention or time since surgery or another procedure, tends to be ignored in most presentations of adverse events. Analyses by time intervals can provide a more informative analysis that makes it possible to view changes in the comparative risk of adverse events changes over the course of a clinical trial. Dividing the study into multiple time intervals results in more comparisons and greater potential for type I errors. The methods discussed earlier apply. A single reference line can be used to indicate statistical significance across the time intervals.</p>
<p>The nicardipine trial [<xref ref-type="bibr" rid="bibr1-1740774513485311">1</xref>] had a variable dosing period, with the minimum and maximum number of dosing days being 1 and 27, respectively. In all, 75% of patients had completed dosing by day 12. To examine the influence of time on event risk, we defined several nonoverlapping time intervals and computed incidence separately within each interval; events were assigned to a particular interval when the start day of the event fell within the interval. For the nicardipine trial, we defined several intervals of 3-day duration based on study days: 1–3, 4–6, 7–9, and 10–12. <xref ref-type="fig" rid="fig4-1740774513485311">Figure 4</xref> summarizes the incidence analysis in four panels for events showing statistically significant differences between treatment arms in at least one time interval. Over the course of the four time intervals, the risk and statistical significance of the difference in incidence of phlebitis increased for nicardipine compared to placebo, while the risk of hypotension decreased. We concluded that the treatment difference for vasoconstriction remained relatively constant for the later three time intervals.</p>
<p>The optimal number of displayed time intervals can be difficult to estimate in advance. The number of intervals selected for analysis of temporal changes should strike a balance between viewing comparative risk changes over time and the loss of power for treatment comparisons when many time periods are selected. The particular therapeutic area or pharmacokinetics of a drug may suggest appropriate intervals; clinical investigators who are members of the study team may have suggestions.</p>
</sec>
</sec>
<sec id="section15-1740774513485311" sec-type="discussion">
<title>Discussion</title>
<p>We have shown that volcano plots are space-conserving visual displays that can be used to emphasize important differences between the adverse event profiles of two treatment arms. They can incorporate multiplicity adjustments in a manner that is straightforward to interpret and can be used to illustrate changes in adverse event risk during a clinical trial. Whether through the use of multiple plots or animation, volcano plots can provide insight into how risk changes over the course of the clinical trial, and may suggest hypotheses for more formal statistical testing. Volcano plots may not provide advantages over traditional methods for examining adverse events in therapeutic areas where few adverse events are expected, such as small trials of minimal duration. However, for potentially life-threatening diseases, diseases where adverse events often recur, or in trials with large numbers of patients or of long duration, volcano plots can be useful to compare the safety profiles of the treatments under investigation.</p>
<p>In comparison to volcano plots, the relative risk plot (<xref ref-type="fig" rid="fig1-1740774513485311">Figure 1</xref>) generally requires more space in order to summarize each confidence interval, and the dot plot portion of <xref ref-type="fig" rid="fig1-1740774513485311">Figure 1</xref> may require a lot of space when events occur at greatly varying rates. While individual treatment arm event rates are not available directly in volcano plots as they are in <xref ref-type="fig" rid="fig1-1740774513485311">Figure 1</xref>, software can be constructed to provide rates (as well as other information) when the user hovers over individual terms while viewing plots interactively. When not working interactively, however, summary tables may be necessary to access additional analysis details. When results are presented across time intervals, viewers of volcano plots benefit from the use of animation to convey changing risk profiles. Such changes are difficult to appreciate and interpret with a relative risk plot.</p>
<p>One downside of both methods of data display is that they limit comparisons to pairs of treatments. However, a three-dimensional volcano plot could present event risk for three treatments, or a trellis of all possible treatment pairs could be used to present either volcano or relative risk plots. The use of color for volcano plots reinforces information available from the <italic>x</italic>- and <italic>y</italic>-axes. Alternatively, bubbles could be colored by system organ class to highlight related events or by some other characteristic such as event severity. Of course, the use of color nuances to convey important differentiation information relies on accurate final color rendering.</p>
<p>Multiplicity is an important consideration for any safety presentation, and a careful balance between minimizing type I errors without greatly sacrificing power is critical. Multiplicity concerns are particularly important when specifying multiple time intervals. One way to reduce the number of hypotheses is to limit the analysis to those events that occur at a certain frequency, say 5% or greater. Of course, defining time intervals is likely to be useful only for the more commonly occurring adverse events. However, one possibility for the graphical presentation of rare events is to summarize by system organ class. Then, the changes in incidence of system organ classes for these rare events can be examined over time. Alternatively, a meta-analysis of several studies could be performed using stratified versions of statistical tests.</p>
<p>Finally, though discussed in the context of summarizing adverse event incidence, volcano plots can be applied to other areas in the analysis of safety data. For example, the frequency of laboratory abnormalities could be summarized across time using time intervals defined by using study days or visits. Therapeutic areas in which patients are treated with numerous concomitant medications could benefit from the use of volcano plots to summarize differences in medication use between treatment arms. In these instances, World Health Organization (WHO) Drug coding of concomitant medications can allow the analyst to consider medication classes in order to apply DFDR. For diseases with multiple secondary efficacy endpoints repeatedly measured across time, volcano plots can be a straightforward way to gain insight into treatment effects across time, after accounting for multiplicity.</p>
</sec>
</body>
<back>
<ack>
<p>The authors thank the deputy editor and two referees for the constructive comments and suggestions that improved the content of this article. The authors are grateful for the support and insights of several colleagues: Xan Gregg, Ed Helton, Gene Lightfoot, Kelci Miclaus, and Anisa Scott.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1740774513485311">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haley</surname><given-names>EC</given-names></name>
<name><surname>Kassell</surname><given-names>NF</given-names></name>
<name><surname>Torner</surname><given-names>JC</given-names></name>
</person-group>. <article-title>A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage</article-title>. <source>J Neurosurg</source> <year>1993</year>; <volume>78</volume>: <fpage>537</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr2-1740774513485311">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Amit</surname><given-names>O</given-names></name>
<name><surname>Heiberger</surname><given-names>RM</given-names></name>
<name><surname>Lane</surname><given-names>PW</given-names></name>
</person-group>. <article-title>Graphical approaches to the analysis of safety data from clinical trials</article-title>. <source>Pharm Stat</source> <year>2008</year>; <volume>7</volume>: <fpage>20</fpage>–<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr3-1740774513485311">
<label>3.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Stokes</surname><given-names>ME</given-names></name>
<name><surname>Davis</surname><given-names>CS</given-names></name>
<name><surname>Koch</surname><given-names>GG</given-names></name>
</person-group>. <source>Categorical Data Analysis Using the SAS®System</source> (<edition>3rd edn</edition>). <publisher-name>SAS Institute, Inc.</publisher-name>, <publisher-loc>Cary, NC</publisher-loc>, <year>2012</year>.</citation>
</ref>
<ref id="bibr4-1740774513485311">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jin</surname><given-names>W</given-names></name>
<name><surname>Riley</surname><given-names>RM</given-names></name>
<name><surname>Wolfinger</surname><given-names>RD</given-names></name>
<etal/>
</person-group>. <article-title>The contributions of sex, genotype and age to transcriptional variance in Drosophila melanogaster</article-title>. <source>Nat Genet</source> <year>2001</year>; <volume>29</volume>: <fpage>389</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr5-1740774513485311">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crowe</surname><given-names>BJ</given-names></name>
<name><surname>Xia</surname><given-names>HA</given-names></name>
<name><surname>Berlin</surname><given-names>JA</given-names></name>
<etal/>
</person-group>. <article-title>Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: A report of the safety planning, evaluation, and reporting team</article-title>. <source>Clin Trials</source> <year>2009</year>; <volume>6</volume>: <fpage>430</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr6-1740774513485311">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benjamini</surname><given-names>Y</given-names></name>
<name><surname>Hochberg</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Controlling the false discovery rate: A practical and powerful approach to multiple testing</article-title>. <source>J Roy Stat Soc B</source> <year>1995</year>; <volume>57</volume>: <fpage>289</fpage>–<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr7-1740774513485311">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mehrotra</surname><given-names>DV</given-names></name>
<name><surname>Heyse</surname><given-names>JF</given-names></name>
</person-group>. <article-title>Use of the false discovery rate for evaluating clinical safety data</article-title>. <source>Stat Methods Med Res</source> <year>2004</year>; <volume>13</volume>: <fpage>227</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr8-1740774513485311">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mehrotra</surname><given-names>DV</given-names></name>
<name><surname>Adewale</surname><given-names>AJ</given-names></name>
</person-group>. <article-title>Flagging clinical adverse experiences: Reducing false discoveries without materially compromising power for detecting true signals</article-title>. <source>Stat Med</source> <year>2012</year>; <volume>31</volume>: <fpage>1918</fpage>–<lpage>30</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>